A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
Institutions: Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Institut Gustave Roussy, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Limoges, Innate Pharma (France), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1985322758
